The New Pancreatic Cancer Pill's 90% Figure Measures Disease Control in 61 Patients
The 90.2% figure is a disease control rate from 61 patients taking daraxonrasib with chemotherapy, in a study with no comparison group. Here is what it measures, how it sits beside historical chemotherapy and the 500-patient RASolute 302 trial, and who the FDA's Aug 26, 2026 approval covers.
views
The 90% figure attached to the new pancreatic cancer pill (90.2%, to be exact) is a disease control rate from a study of 61 people. It is the share whose tumours shrank or stopped growing while they took a daily pill alongside chemotherapy. It records what scans showed. It is not a cure rate, and on its own it does not say how much longer anyone lived.
The pill is daraxonrasib, and all 61 people got the same combination. As a report on the early results points out, the study had no randomised control arm, so nobody in it had chemotherapy alone to compare against. The same report quotes Dr Wungki Park of Memorial Sloan Kettering describing the response as "the closest to cure", not a cure.
The same drug already has a US approval. That approval uses a different dose, 300 mg rather than 200 mg, covers patients defined on the label, and rests on RASolute 302, a randomised trial of 500 people compared with the 61 here. Headlines like round numbers and drug labels run on fine print. In this story they describe different things.
Does the pill stop tumours in 90%?
Disease control is the widest count a scan can give. It takes everyone whose tumours shrank and adds everyone whose tumours held steady. In the 61-patient study it was 90.2%, according to RTE's report of the results.

Response is the narrower count: only the tumours that got smaller. Of the 61, 60.7% had tumours that shrank or disappeared, and 8.2% had a complete response. All of these figures come from RTE's news coverage of the data.
Survival takes longer to collect because it measures time: how long people lived, or how long before the cancer got worse. In RTE's figures, 76.6% of the 61 were alive at 12 months, and the median time before the disease worsened was 12.8 months. For scale, National Geographic gives five-year survival for stage IV pancreatic cancer as 3%.
Who was studied?
Three groups of people, in three studies that share one drug name and are easy to mix up:
- The 61-patient combination study: daraxonrasib 200 mg a day plus two chemotherapy drugs, gemcitabine and nab-paclitaxel, with no randomised control arm. The 90.2% comes from this one.
- GI-102: an earlier group of 40 people whose metastatic pancreatic cancer had not been treated, on the same 200 mg dose and the same chemotherapy. It reported a 90% disease control rate.
- RASolute 302: 500 people split one to one between daraxonrasib and chemotherapy chosen by their doctor. This is the trial behind the US approval.
The details of the 61-patient study come from Gulf News: a 200 mg tablet once a day, taken with gemcitabine and nab-paclitaxel. With no chemotherapy-only arm, the results are set against how past patients did on chemotherapy. Gulf News notes that comparisons with historical results like these cannot show whether the combination improves survival.
The 40-patient group is a useful cross-check because it used the same dose and the same chemotherapy. OncLive's report gives a disease control rate of 90%, with a 95% confidence interval of 76% to 97%. Tumours shrank in 58% of patients, 84% were free of progression at six months, and the data cutoff was Dec 1, 2025. The study's primary endpoint was safety.
How does it compare with chemotherapy?
For a head-to-head comparison, these sources have RASolute 302, which is not the trial behind the 90%. The FDA's approval notice describes it as daraxonrasib against chemotherapy of the doctor's choice. People on daraxonrasib lived a median of 13.2 months, against 6.7 months on chemotherapy, a hazard ratio of 0.40. The median time before the cancer worsened was 7.2 months against 3.6 months, a hazard ratio of 0.49. A hazard ratio below 1 favours the drug.
| Measure | 61-patient combination study | Historical chemotherapy | RASolute 302: daraxonrasib vs chemotherapy | Source, column by column |
|---|---|---|---|---|
| Tumours shrank (response) | 60.7% | 23% to 42% | 30% vs 11% | RTE; Gulf News, citing EORTC; FDA |
| Survival | 76.6% alive at 12 months | 8 to 11 months (Gulf News, citing EORTC); around 40% to 45% alive at one year (RTE) | Median 13.2 vs 6.7 months | RTE; Gulf News and RTE, as marked; FDA |
| Disease progression | Median 12.8 months before worsening | Progression after 5 to 6 months | Median 7.2 vs 3.6 months | RTE; Gulf News, citing EORTC; FDA |
Note: each column is a different group of patients, and only the RASolute 302 pair comes from one randomised trial.
The columns also differ in dose and in where the figures come from. The combination study used 200 mg with gemcitabine and nab-paclitaxel, while the approved dose from RASolute 302 is 300 mg. The historical ranges come from earlier chemotherapy studies, which Gulf News attributes to the EORTC, and the one-year figure of around 40% to 45% is RTE's. None of these historical figures is a control group for the 61.
Side effect figures cover different regimens, so they don't line up either. In the 40-patient GI-102 group, on 200 mg with gemcitabine and nab-paclitaxel, 73% had treatment-related side effects of grade 3 or worse (severe or worse), OncLive reports. In the 61-patient combination study, 5% stopped because of side effects, according to Gulf News. For RASolute 302, daraxonrasib against chemotherapy, National Geographic gives grade 3 or worse adverse events in 61.8% of people on daraxonrasib and 69.6% on chemotherapy. In the same trial, 1.2% stopped the pill because of side effects and 11.2% stopped chemotherapy.
What is still unknown?
Mostly, whether adding the pill to chemotherapy helps people live longer than chemotherapy alone. The 61-patient study cannot show that without a chemotherapy-only arm. The sources also do not say whether the 61 had been treated before. Their survival is reported at one year, so how long they lived after that is not yet known. The EORTC abstract was not found at the time of writing.
Who can get it, and when?
In the US, some adults can get the pill now, on the label's terms. The FDA approved daraxonrasib, sold as RASONQUE, on Aug 26, 2026. The approval covers adults with metastatic pancreatic adenocarcinoma who have had at least one earlier systemic therapy, or who are not candidates for multiagent therapy (chemotherapy using several drugs). The label dose is 300 mg by mouth once a day, taken until the disease progresses or the side effects become unacceptable.

The FDA label does not cover the combination behind the 90%, which is 200 mg with gemcitabine and nab-paclitaxel. National Geographic notes that the pill has not been shown to be the preferred first treatment, and that combination chemotherapy remains the standard first treatment for most patients who can tolerate it. Phase 3 testing is under way. Gulf News names RASolute-303. RTE says the US phase 3 study has enough patients. National Geographic lists NCT07491445 as testing the drug in untreated disease.
In the UK, RTE quotes Michelle Mitchell of Cancer Research UK saying that more trials are needed before the treatment can be assessed for use on the NHS.
The next results to watch are from those phase 3 trials, and no date for them has been reported. The 90.2% is promising, and it is not a claim of cure.
Tomasz Kowalczyk
Tomasz Kowalczyk writes the home and family guides. Father of two, near Krakow.
View profileMore from Tomasz Kowalczyk
View all →Recommended for you
More stories →
Yale analysis finds drugs and exercise lowered epigenetic age, supplements did not
American Cancer Society now recommends PSA tests every two years for men 50 to 69
Foundayo for Sleep Apnea: What the Trial Shows Next to Zepbound and CPAP
Leave a Comment